1. Chair:Dr. Vivien Bramwell NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP Sarcoma Committee CANADIAN SARCOMA GROUP

2. Objectives - short-term 1.To undertake adjuvant studies to reduce recurrence and mortality due to metastases in early ASTS (Intergroup) GISTACOSOG Z9001GISTACOSOG Z9001 -will complete accrual in 6 - 12 months -Canadian accrual approx. 10% STSINTERGROUPSTSINTERGROUP -Canadian participation in EORTC 62931 (closed December 2003) December 2003) -several Intergroup proposals for RCT have failed, no agreement on appropriate control arm, limited efficacy current regimens in advanced STS SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP

3. Objectives - short-term 2.To perform empirical screening and/or rationally targeted studies of IND in chemotherapy-naïve patients across spectrum ASTS four phase II studies completed, published in last 10 yrsfour phase II studies completed, published in last 10 yrs chemo-naïve patients, Intergroup collaboration in EORTC 62012chemo-naïve patients, Intergroup collaboration in EORTC 62012 – phase III trial of single agent DOX vs dose intense DOX/IFOS – start Fall 2006 SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP

4. Objectives - short-term 3.To assess molecularly targeted therapies in histology- specific trials in patients who have failed conventional chemotherapy (Intergroup) ICASIntergroup Coalition Against Sarcomas funded through SWOG operating grantfunded through SWOG operating grant involves NCIC-CTG, ECOG, CALGBinvolves NCIC-CTG, ECOG, CALGB shared studies with RTOG, ACOSOG, COG S0033 imatinib in GIST (closed September 2001)S0033 imatinib in GIST (closed September 2001) – accrued 746 pts in 9 mos (Canadian 7%) 4 IND studies open – accruing through SWOG4 IND studies open – accruing through SWOG 3 on CTSU (1 awaiting Canadian activation, 2 declined)3 on CTSU (1 awaiting Canadian activation, 2 declined) 3 future ICAS CTSU studies – Canadian interest3 future ICAS CTSU studies – Canadian interest 1 protocol, Canadian PI (Q. Chu) in development1 protocol, Canadian PI (Q. Chu) in development SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP

5. Objectives - medium-term 4.To use research findings generated through the CSG TB/DB and/or IHRT program to plan future correlative science projects/clinical trials CSG TB/DB (approximately 900 frozen/fixed tumors and data) currently funded and maintained as part of larger TB/DB through IHRT program Mt. Sinai, TorontoCSG TB/DB (approximately 900 frozen/fixed tumors and data) currently funded and maintained as part of larger TB/DB through IHRT program Mt. Sinai, Toronto IHRT program may morph into CanSarc (pending funding CIHR)IHRT program may morph into CanSarc (pending funding CIHR) IHRT/CanSarc projects, in future, may need national clinical trials involvementIHRT/CanSarc projects, in future, may need national clinical trials involvement SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP

6. 5.To build on local control, survival and functional outcome data from SR2 study, to plan future studies that will optimize local control and reduce morbidity in locoregional ASTS translational, pilot studies ongoing through IHRT/CanSarctranslational, pilot studies ongoing through IHRT/CanSarc also may lead to future proposals for multicentre trialsalso may lead to future proposals for multicentre trials SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP Objectives - medium-term